Since the majority of cancer patients do not have tumor remission following ICIs, researchers have attempted combination strategies; for example, anti-CTLA-4 agents have been utilized along with anti-PD-1 and PD-L1 [66,67]. This evidence concerns the gene CD274 and cancer.